News
12-14-2010, 04:50 AM
Unigene Laboratories, Inc. today announced that the Company entered into an amended and restated exclusive worldwide license agreement with GlaxoSmithKline (GSK) to develop and commercialize an oral formulation of a recombinantly produced parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women and plans to initiate a Phase 2 study in the first quarter of 2011.
More... (http://www.news-medical.net/news/20101214/Unigene-enters-agreement-with-GSK-to-advance-oral-PTH-Phase-2-program-for-osteoporosis.aspx)
More... (http://www.news-medical.net/news/20101214/Unigene-enters-agreement-with-GSK-to-advance-oral-PTH-Phase-2-program-for-osteoporosis.aspx)